US Mental Health Parity law criticized
An attempt to introduce mental health legislation in the US Congress has come under attack from both insurers and the drug industry. The America's Health Insurance Plans and the Pharmaceutical Research and Manufacturers of America (PhRMA; see page 27) were especially critical of the House of Representatives' version of the proposed law (HR 1424).
The mental health parity law under discussion involves the establishment of mental health benefits in line with medical and surgical benefits under the Medicaid program.
Karen Ignagni, the AHIP's president, said: "millions of Americans are challenged by serious mental health conditions and ensuring appropriate treatment and coverage is an important priority for all health care stakeholders." She added that "over the past decade, health insurance plans have responded by offering innovative programs and increasingly flexible benefit options."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze